November 22, 2013 / 1:44 PM / 4 years ago

CORRECTED-MARKET PULSE-Ariad Pharmaceuticals

1 Min Read

(Corrects to say the European agency backed continued use of the drug, not that it recommended first approval)

Nov 22 (Reuters) -

** ARIAD PHARMACEUTICALS INC, Thursday close $2.79, up 25 pct premarket

The company said European regulators recommended the continued use of its leukemia drug, Iclusig, whose U.S. sale has been suspended due to safety concerns. (Compiled by Natalie Grover; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below